2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 260-262
Treatment Considerations, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Health Outcomes Research, Real-World Evidence, Study Population, Human, Pediatric, Young Adult
PAPER

1097 Real-world outcomes of bispecific antibody combination regimens in relapsed/refractory large B-cell lymphoma: A realbite consortium analysis

Taylor R. Brooks, MD, Stephanie Franco, MD2, Natalie S Grover, MD3, Adrienne N. Nedved, PharmD, MPA4, Yucai Wang, MD, PhD5, Xi Yang, MD6, Yasmin H Karimi, MD7, Emma Williams, MD, PhD8, Priyanka A. Pophali, MD9, Sally Jones, MD10, Aditi Saha, MD11, Jun Chih Wang, MD12, Jose Sandoval-Sus I, MD13, Tenley Schwarz14, Matthew Schwede, MD, MS15, Rodolfo Garza Morales, MD16, Javier L. Munoz, MD, MBA17, Nikita K Dave, MD18, Daniel Landsburg, MD19, Emma Gray, MD20, Emily Ayers, MD21, Megan Sears-Smith22, Nilanjan Ghosh, MD23, Kelsey Baron, MD24, Boyu Hu, MD25, Saloni Savani, MD26, Cyrus Khan, MD27, Catherine Reinert28, Ajay Major, MD, MBA29, Xiancheng Wu, MD30, Stephen Douglas Smith, MD31, Krisha Mehta, MD32, Joanna M Rhodes, MD, MSCE33, Fadzai Chinyengetere, MDPhD34, Sandeep Dave, MD35, Nayef Abdel-Razeq, MD36, Muhamad Alhaj Moustafa, MD, MS37, Alex Niu, MD38, Francisco Hernandez-Ilizaliturri, MD39, Paolo Fabrizio Caimi, MD40, Brian Hill, MD, PhD41
1 Cleveland Clinic, Cleveland, Ohio, United States
2 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
3 University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 University of Michigan, Ann Arbor, Michigan, United States
7 University of Michigan, Ann Arbor, Michigan, United States
8 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
9 University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
10 University of Alabama, Birmingham, Birmingham, Alabama, United States
11 University of Alabama, Birmingham, Birmingham, Alabama, United States
12 Moffitt Cancer Center, Pembroke Pines, Florida, United States
13 Moffitt Cancer Center, Pembroke Pines, Florida, United States
14 Swedish Cancer Institute, Seattle, Washington, United States
15 Swedish Cancer Institute, Seattle, Washington, United States
16 Mayo Clinic, Phoenix, Arizona, United States
17 Mayo Clinic, Phoenix, Arizona, United States
18 University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
19 University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States
20 University of Virginia, Charlottesville, Virginia, United States
21 University of Virginia, Charlottesville, Virginia, United States
22 Levine Cancer Institute, Charlotte, North Carolina, United States
23 Levine Cancer Institute, Charlotte, North Carolina, United States
24 University of Utah, Salt Lake City, Utah, United States
25 University of Utah, Salt Lake City, Utah, United States
26 Allegheny Health Network, Pittsburgh, Pennsylvania, United States
27 UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
28 University of Colorado Cancer Center, Aurora, Colorado, United States
29 University of Colorado Cancer Center, Aurora, Colorado, United States
30 Fred Hutchinson Cancer Center, Seattle, Washington, United States
31 Fred Hutchinson Cancer Center, Seattle, Washington, United States
32 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
33 Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
34 Duke University, Durham, North Carolina, United States
35 Duke University, Durham, North Carolina, United States
36 Mayo Clinic, Jacksonville, Florida, United States
37 Mayo Clinic, Jacksonville, Florida, United States
38 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
39 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
40 Cleveland Clinic, Cleveland, Ohio, United States
41 Cleveland Clinic, Cleveland, Ohio, United States

Introduction: CD20×CD3 bispecific antibodies (BsAbs) are active in relapsed/refractory (r/r) large B-cell lymphoma (LBCL) but, as real-world monotherapy, yield a median progression-free survival (PFS) under 3 months. Combining BsAbs with chemotherapy or other active agents may deepen and prolong responses, yet real-world data on BsAb combination regimens remain limited. We report the characteristics, efficacy, safety, and treatment patterns of patients treated with BsAb combination regimens in the multicenter REALBiTE consortium.

Methods: We retrospectively analyzed adults with R/R LBCL who received a BsAb-containing combination regimen between 2023 and 2026 across 20 US centers, defined as a CD20×CD3 BsAb (glofitamab, epcoritamab, or mosunetuzumab) with chemotherapy or other agents. Endpoints were overall and complete response rate (ORR/CRR) per Lugano 2014, PFS, overall survival (OS), and duration of response (DoR), estimated by Kaplan-Meier. Cumulative incidence of relapse versus non-relapse mortality (NRM) was assessed by competing-risks analysis, and prognostic associations by univariable and multivariable Cox and logistic models. CRS and ICANS were graded per ASTCT criteria.

Results: Seventy-seven patients were analyzed. Median age was 69 years (IQR 56-78) and 68% were male. DLBCL NOS was the most common histology (84%); 20% had double-hit lymphoma, 43% double-expressor (MYC/BCL2) phenotype, and 27% prior indolent lymphoma. At BsAb initiation, 66% had stage IV disease, 67% IPI >2, 35% ECOG PS >1, 29% bulky disease, and 74% primary refractory disease. Patients had received a median of 1 prior line (IQR 1-2) and 30% prior CAR T-cell therapy. Regimens were predominantly glofitamab-based (77%): glofitamab-GemOx 73%, glofitamab-polatuzumab 4%; mosunetuzumab-polatuzumab 17%; 1 patient received epcoritamab-GemOx. Among 66 response-evaluable patients, ORR was 73% (95% CI 60-83%) and CRR 42% (30-55%), with median time to best response 60 days; response was similar for glofitamab- and mosunetuzumab-based combinations (ORR 73% each). At a median follow-up of 7.2 months, median PFS was 6.0 months (6-/12-month PFS 51%/46%) and median OS 16.3 months (6-/12-month OS 70%/64%); median DoR was not reached (6-/12-month 71%/57%). Outcomes favored treatment following one versus ≥2 prior lines (ORR 82% vs 58%; median PFS 12.4 vs 3.5 months, p=0.047). Treatment failure was driven by relapse (12-month cumulative incidence 50%), with NRM of 8%. In multivariable analysis, primary refractory disease was independently associated with inferior PFS (HR 5.06; 95% CI 1.49-17.17); no covariate predicted OS, though the number of deaths (n=23) limited model power. Any-grade CRS occurred in 44% (grade ≥2, 16%; grade ≥3, 5%) and ICANS in 4%; tocilizumab and rescue corticosteroids were given in 21% and 31%. Infection was the attributed cause in 4 deaths (5%; 17% of deaths) and progression in 52%. CD20-negativity prior to BsAb (n=4) was associated with markedly inferior OS (median 2.2 vs 16.3 months; p=0.004) and lower ORR (50% vs 85%). Prior CAR T preceded BsAb by a median of 5.4 months; response was higher when the combination began >100 versus ≤100 days after CAR T (ORR 79% vs 25%). Twelve patients (16%) received subsequent CAR T-cell therapy, given as consolidation in 9 (75%) and salvage for progression in 3 (25%); products were liso-cel (58%) and axi-cel (42%). Among 11 evaluable, ORR to subsequent CAR T was 82% and CRR 45%, with numerically deeper responses as consolidation than salvage (ORR 88% vs 67%; CR 50% vs 33%).

Conclusions: In this real-world cohort, BsAb-based combination regimens (predominantly glofitamab-GemOx) produced high response rates and encouraging early survival in a high-risk, largely refractory r/r LBCL population, with low rates of high-grade CRS, ICANS, and NRM. Treatment failure was driven by relapse rather than toxicity. Subsequent CD19 CAR T-cell therapy after a BsAb combination was administered predominantly as consolidation rather than salvage and retained meaningful activity, with numerically deeper responses as consolidation, though sample size is small. These data suggest BsAb-based combinations may serve as an effective platform for sequencing to CD19 CAR T-cell therapy and support further prospective evaluation in R/R LBCL.

Taylor R. Brooks, MD: No relevant conflicts of interest to declare.